July 24, 2019 | City of Hope
An study conducted by Michael Caligiuri, M.D., and Jianhua Yu, Ph.D., unveiled why anti-PD-L1 monoclonal antibodies (mAb) are still effective in fighting tumors that lack PD-L1 receptors on their cells.
Saswati Chatterjee, Ph.D., Seeks Cure for Hemophilia
February 21, 2018 | Katie Neith
Saswati Chatterjee, Ph.D., a professor in the Department of Surgery and member of Beckman Research Institute of City of Hope, thinks she may know a way to cure hemophilia A.
Larry Kwak, M.D., Ph.D., Receives Grant for Promising Lymphoma Work
January 12, 2018 | Letisia Marquez
Larry Kwak, M.D., Ph.D., received a grant to support his work with mantle cell lymphoma from the Leukemia & Lymphoma Society, the world’s largest voluntary health organization dedicated to fighting blood cancer.
Multiple Myeloma CAR T Cell Trial to launch in 2017
April 3, 2017 | Travis Marshall
An upcoming phase 1 clinical trial at City of Hope will look at the effects of CAR T cells programmed to target a protein called CS-1, which is found on myeloma cells.
Researchers tackle two difficult-to-treat lymphomas
February 2, 2017 | Letisia Marquez
New study in the Journal of Clinical Oncology concludes that patients with relapsed or treatment-resistant double-hit and/or double-expressor lymphomas didn’t respond as well to the transplantation as diffuse large B-cell lymphoma patients who did not have those types of lymphoma.
Hodgkin Lymphoma Trial Results Promising
January 9, 2017 | Abe Rosenberg
Everything changed when a Hodgkin lymphoma patient joined a Phase II clinical trial examining the effectiveness of brentuximab vedotin (BV) after a failed transplant. The BV worked immediately, achieving a complete remission which, year after year, proved to be durable beyond anyone's expectations.
Steven T. Rosen, M.D. on the Latest Breakthroughs in Blood Cancer Treatment
December 16, 2016 | City of Hope
The long-term strategies offered by City of Hope’s Hematologic Malignancies (HM) Program have dramatically improved the lives of patients with leukemia, lymphoma, Hodgkin’s disease and multiple myeloma.
ASH 2016: Innovative new trials show promise for lymphoma and multiple myeloma patients
December 7, 2016 | City of Hope
Numerous clinical trials, which lay the groundwork for novel approaches to lymphoma and multiple myeloma therapies, could ultimately lead to new treatments that improve survival and quality of life for patients with those and other diseases. Additional studies give new insight into best practices for the treatment of various blood cancers.